Search results
Results from the WOW.Com Content Network
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...
The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's ...
Donanemab is given to patients via an intravenous drip once every four weeks. Lilly has said that some patients can complete their course of treatment in as little as six months once their amyloid ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [31] [32] Donanemab was developed by Eli Lilly and Company. [33] [34] The most common side effects include amyloid-related imaging abnormalities and headache. [32] Donanemab was approved for medical use in the United States in ...
The drug donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. ... The agency’s approval was based on a late-stage clinical trial ...
The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
The drug donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. ... The agency’s approval was based on a late-stage clinical trial ...